1,396 results on '"Shiku, Hiroshi"'
Search Results
2. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex
3. Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model
4. αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence
5. Fully closed cell sorter for immune cell therapy manufacturing
6. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy
7. Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance
8. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients
9. Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia
10. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
11. Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report
12. O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS
13. TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
14. Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
15. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination
16. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance
17. Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells
18. Defining the Critical Hurdles in Cancer Immunotherapy
19. Accelerated Chemically Induced Tumor Development Mediated by CD4 + CD25 + Regulatory T Cells in Wild-Type Hosts
20. T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease
21. Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model
22. Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology
23. $CD4^+\>CD25^+$ T Cells Responding to Serologically Defined Autoantigens Suppress Antitumor Immune Responses
24. Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS
25. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
26. Role of SEREX-Defined Immunogenic Wild-Type Cellular Molecules in the Development of Tumor-Specific Immunity
27. Complex Gangliosides are Essential in Spermatogenesis of Mice: Possible Roles in the Transport of Testosterone
28. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy
29. Modern T cell technologies for immunotherapy of solid tumors
30. Data from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy
31. Supplementary Figure 1 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy
32. Supplementary Figure 2 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy
33. Mutated Mitogen-Activated Protein Kinase: A Tumor Rejection Antigen of Mouse Sarcoma
34. Mice with Disrupted GM2/GD2 Synthase Gene Lack Complex Gangliosides but Exhibit Only Subtle Defects in their Nervous System
35. Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells
36. CD8⁺CD122⁺CD49d low regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity
37. Supplementary Figure S3 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
38. Supplementary Figure S1 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
39. Supplementary Data from Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
40. Supplementary Table S1 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
41. Supplementary Table S1 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
42. Data from Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
43. Supplementary Figure Legend from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
44. Data from Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
45. Supplementary Figure 2 from Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR
46. Supplementary Figure Legends 1-3 from Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR
47. Data from Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
48. Supplementary Figure 3 from Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR
49. Supplementary Figure 1 from Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR
50. Data from Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.